Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016

Choose Licence

 

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016 Summary Global Markets Directs, Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H2 2016?, provides an overview of the Metastatic Adenocarcinoma of The Pancreas pipeline landscape. The report provides comprehensive information on the therapeutics under development for Metastatic Adenocarcinoma of The Pancreas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Adenocarcinoma of The Pancreas and features dormant and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas - The report reviews pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Metastatic Adenocarcinoma of The Pancreas therapeutics and enlists all their major and minor projects - The report assesses Metastatic Adenocarcinoma of The Pancreas therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Metastatic Adenocarcinoma of The Pancreas Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Metastatic Adenocarcinoma of The Pancreas Overview 10 Therapeutics Development 11 Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview 11 Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis 12 Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies 13 Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes 15 Metastatic Adenocarcinoma of The Pancreas - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies 19 Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes 21 Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development 22 AbbVie Inc 22 Aduro BioTech, Inc. 23 Array BioPharma Inc. 24 Axcentua Pharmaceuticals AB 25 Berg LLC 26 Boehringer Ingelheim GmbH 27 Boston Biomedical, Inc. 28 CTI BioPharma Corp. 29 CytRx Corporation 30 Daiichi Sankyo Company, Limited 31 Eleison Pharmaceuticals LLC 32 Gilead Sciences, Inc. 33 GlaxoSmithKline Plc 34 Incyte Corporation 35 MabVax Therapeutics Holdings, Inc. 36 Merrimack Pharmaceuticals, Inc. 37 NewLink Genetics Corporation 38 Novartis AG 39 Oncolytics Biotech Inc. 40 Pfizer Inc. 41 Phoenix Biotechnology, Inc. 42 Targovax ASA 43 Metastatic Adenocarcinoma of The Pancreas - Therapeutics Assessment 44 Assessment by Monotherapy Products 44 Assessment by Combination Products 45 Assessment by Target 46 Assessment by Mechanism of Action 49 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 (curcumin + gemcitabine hydrochloride + paclitaxel) - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 aldoxorubicin hydrochloride - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 AXP-10711 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 BI-853520 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 binimetinib - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Cellular Immunotherapy for Oncology - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Cellular Immunotherapy for Oncology - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 ceritinib - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 glufosfamide - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 GS-5745 - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 GSK-2256098 - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 HuMab-5B1 - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 ibrutinib - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 INCB-52793 - Drug Profile 125 Product Description 125 Mechanism Of Action 125 R&D Progress 125 indoximod - Drug Profile 126 Product Description 126 Mechanism Of Action 126 R&D Progress 126 irinotecan hydrochloride - Drug Profile 131 Product Description 131 Mechanism Of Action 131 R&D Progress 131 MesoCART - Drug Profile 142 Product Description 142 Mechanism Of Action 142 R&D Progress 142 Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile 143 Product Description 143 Mechanism Of Action 143 R&D Progress 143 napabucasin - Drug Profile 145 Product Description 145 Mechanism Of Action 145 R&D Progress 145 nimotuzumab - Drug Profile 151 Product Description 151 Mechanism Of Action 151 R&D Progress 151 palbociclib - Drug Profile 155 Product Description 155 Mechanism Of Action 155 R&D Progress 155 PBI-05204 - Drug Profile 165 Product Description 165 Mechanism Of Action 165 R&D Progress 165 pelareorep - Drug Profile 167 Product Description 167 Mechanism Of Action 167 R&D Progress 167 PLX-7486 - Drug Profile 181 Product Description 181 Mechanism Of Action 181 R&D Progress 181 PRI-724 - Drug Profile 182 Product Description 182 Mechanism Of Action 182 R&D Progress 182 ribociclib succinate - Drug Profile 184 Product Description 184 Mechanism Of Action 184 R&D Progress 184 SGT-53 - Drug Profile 188 Product Description 188 Mechanism Of Action 188 R&D Progress 188 sonidegib phosphate - Drug Profile 190 Product Description 190 Mechanism Of Action 190 R&D Progress 190 TG-01 - Drug Profile 195 Product Description 195 Mechanism Of Action 195 R&D Progress 195 tosedostat - Drug Profile 198 Product Description 198 Mechanism Of Action 198 R&D Progress 198 ubidecarenone - Drug Profile 203 Product Description 203 Mechanism Of Action 203 R&D Progress 203 ulixertinib - Drug Profile 206 Product Description 206 Mechanism Of Action 206 R&D Progress 206 Vaccine for Oncology - Drug Profile 207 Product Description 207 Mechanism Of Action 207 R&D Progress 207 Metastatic Adenocarcinoma of The Pancreas - Dormant Projects 208 Metastatic Adenocarcinoma of The Pancreas - Discontinued Products 209 Metastatic Adenocarcinoma of The Pancreas - Product Development Milestones 210 Featured News & Press Releases 210 Aug 04, 2016: Merrimack Provides Update on ONIVYDE 210 Jul 21, 2016: Baxalta receives CHMP positive opinion on Onivyde for the treatment of metastatic adenocarcinoma of the pancreas 210 Jun 21, 2016: Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer 211 May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016 211 Apr 14, 2016: Targovax reports immune response with reduced number of TG01 vaccinations 212 Jan 25, 2016: Boston Biomedical?s Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium 212 Jan 07, 2016: Baxalta Announces Priority Review Status Granted by Health Canada for irinotecan liposome injection (nal-IRI) for New Drug Submission 214 Jun 25, 2015: MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer 215 Appendix 216 Methodology 216 Coverage 216 Secondary Research 216 Primary Research 216 Expert Panel Validation 216 Contact Us 216 Disclaimer 217

List of Tables Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H2 2016 11 Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Number of Products under Development by Companies, H2 2016 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Comparative Analysis by Late Stage Development, H2 2016 16 Comparative Analysis by Clinical Stage Development, H2 2016 17 Comparative Analysis by Early Stage Development, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Development by Companies, H2 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H2 2016 21 Metastatic Adenocarcinoma of The Pancreas - Pipeline by AbbVie Inc, H2 2016 22 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Aduro BioTech, Inc., H2 2016 23 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Array BioPharma Inc., H2 2016 24 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Axcentua Pharmaceuticals AB, H2 2016 25 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Berg LLC, H2 2016 26 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boehringer Ingelheim GmbH, H2 2016 27 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Boston Biomedical, Inc., H2 2016 28 Metastatic Adenocarcinoma of The Pancreas - Pipeline by CTI BioPharma Corp., H2 2016 29 Metastatic Adenocarcinoma of The Pancreas - Pipeline by CytRx Corporation, H2 2016 30 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 31 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Eleison Pharmaceuticals LLC, H2 2016 32 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Gilead Sciences, Inc., H2 2016 33 Metastatic Adenocarcinoma of The Pancreas - Pipeline by GlaxoSmithKline Plc, H2 2016 34 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Incyte Corporation, H2 2016 35 Metastatic Adenocarcinoma of The Pancreas - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016 36 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 37 Metastatic Adenocarcinoma of The Pancreas - Pipeline by NewLink Genetics Corporation, H2 2016 38 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Novartis AG, H2 2016 39 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Oncolytics Biotech Inc., H2 2016 40 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Pfizer Inc., H2 2016 41 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Phoenix Biotechnology, Inc., H2 2016 42 Metastatic Adenocarcinoma of The Pancreas - Pipeline by Targovax ASA, H2 2016 43 Assessment by Monotherapy Products, H2 2016 44 Assessment by Combination Products, H2 2016 45 Number of Products by Stage and Target, H2 2016 47 Number of Products by Stage and Mechanism of Action, H2 2016 50 Number of Products by Stage and Route of Administration, H2 2016 53 Number of Products by Stage and Molecule Type, H2 2016 55 Metastatic Adenocarcinoma of The Pancreas - Dormant Projects, H2 2016 208 Metastatic Adenocarcinoma of The Pancreas - Discontinued Products, H2 2016 209


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining b...

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017 Summary According to the recently published report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017'; Transthyretin (ATTR or Prealbumin or TBP...

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein...

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximat...

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the re...

New Pharmaceuticals and Healthcare Reports